We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+9.24%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$430M
AUM Growth
-$55.3M
Cap. Flow
-$49.8M
Cap. Flow %
-11.57%
Top 10 Hldgs %
92.29%
Holding
20
New
–
Increased
1
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$32.6K

Top Sells

Rank Stock Value
1
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$45.1M
2
AGRX
Agile Therapeutics
AGRX
+$3.31M
3
EVAR
Lombard Medical, Inc.
EVAR
+$417K
4
XENT
Intersect ENT, Inc
XENT
+$304K

Sector Composition

Rank Sector Weight
1 Healthcare 73.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$129M 30.09%
4,028,920
– –
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$70.1M 16.29%
1,609,727
– –
AIMT
3
DELISTED
Aimmune Therapeutics
AIMT
$61.1M 14.22%
2,990,000
– –
ARAV
4
DELISTED
Aravive, Inc. Common Stock
ARAV
$37.6M 8.74%
420,744
– –
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
$23.4M 5.44%
7,480,887
– –
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$20.5M 4.77%
1,637,125
– –
ADMA icon
7
ADMA Biologics
ADMA
$2.03B
$18.5M 4.29%
3,608,171
– –
TTOO
8
DELISTED
T2 Biosystems, Inc
TTOO
$14.9M 3.46%
566
– –
ASXC
9
DELISTED
Asensus Surgical, Inc.
ASXC
$10.8M 2.52%
641,217
– –
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$10.6M 2.47%
51,057
– –
AGRX
11
DELISTED
Agile Therapeutics
AGRX
$10.3M 2.39%
902
-236
-21% -$3.31M
PRTK
12
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.43M 1.73%
482,680
– –
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.18M 1.44%
50,857
– –
CEMP
14
DELISTED
Cempra, Inc.
CEMP
$3.34M 0.78%
1,193,060
– –
XENT
15
DELISTED
Intersect ENT, Inc
XENT
$2.72M 0.63%
225,000
-23,498
-9% -$304K
CMRX
16
DELISTED
Chimerix, Inc.
CMRX
$2.18M 0.51%
472,943
– –
PTX
17
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$407K 0.09%
210,000
+9,000
+4% +$32.6K
EVAR
18
DELISTED
Lombard Medical, Inc.
EVAR
– –
-443,182
Closed -$417K
CYNA
19
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-1,121,381
Closed -$45.1M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Aisling Capital held 20 positions worth $430M, down 11% from $485M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Aisling Capital withdrew a net $49.8M in Q4 2016, closing 2 positions and reducing 2 holdings. Its most notable exit was CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA), an estimated $45.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier.

Against the trend, Aisling Capital added an estimated $32.6K to Pernix Therapeutics Holdings, Inc..

  • Aisling Capital added most to Pernix Therapeutics Holdings, Inc. in Q4 2016, an estimated $32.6K increase.
  • Aisling Capital's biggest Q4 2016 reduction was Agile Therapeutics, cutting an estimated $3.31M.
  • Aisling Capital fully exited CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q4 2016, selling an estimated $45.1M.
  • Aisling Capital's ten largest holdings make up 92% of its $430M portfolio in Q4 2016.
  • Aisling Capital opened 0 new positions and closed 2 in Q4 2016.
  • Aisling Capital's portfolio value fell 11% quarter-over-quarter to $430M.

Based on Aisling Capital's 13F filing for Q4 2016, filed 13 Feb 2017.